Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ERAS-007 + Sotorasib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ERAS-007 | ASN007|ASN-007|ASN 007|ERAS007|ERAS 007 | ERK Inhibitor (pan) 21 | ERAS-007 (ASN007) is a small molecule that inhibits ERK1/2, which may result in decreased tumor cell proliferation and reduced tumor growth (PMID: 34337566). | |
Sotorasib | Lumakras | AMG 510|AMG510|AMG-510|Lumykras | KRAS G12C inhibitor 34 | Lumakras (sotorasib) is small molecule inhibitor that selectively targets KRAS G12C and inhibits downstream signaling, which may lead to growth inhibition of tumors harboring KRAS G12C (PMID: 31666701). Lumakras (sotorasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04959981 | Phase Ib/II | ERAS-007 + Osimertinib ERAS-601 + Sotorasib ERAS-007 + Sotorasib | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2) | Completed | USA | 0 |